WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.
Size
1 mL
Concentration
10.0 million cells/ml
Applications
The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways.
Other Names
Human Melanoma, patient derived tumor, tumor models, skin cancer, xenograft